NINTEDANIB was granted orphan drug designation for the treatment of mesothelioma. The agent is sponsored by Boehringer Ingelheim Nintedanib is an oral triple angiokinase inhibitor which simultaneously inhibits vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR) and fibroblast growth factor receptors (FGFR 1-3) signaling pathways. These three different angiokinase receptors, which... […]
THE OBAMA ADMINISTRATION has abandoned its controversial plan to change the way Medicare pays for drugs. The decision to abandon the proposal called the Medicare Part B Drug Payment Model was announced late Dec. 15. The model ran into opposition from the pharmaceutical lobby, physician groups, Republicans and many Democrats on Capitol Hill. With the... […]
ROBERT MAKI, a physician and researcher specializing in sarcoma cancer, joined the leadership of Northwell Health and Cold Spring Harbor Laboratory. Based at the Monter Cancer Center in Lake Success, Maki serves as director of experimental therapeutics of the Don Monti Division of Medical Oncology and Hematology at North Shore University Hospital and Long Island... […]
Fate Therapeutics Inc. said that IND-enabling production of FT500 has commenced at University of Minnesota, Molecular and Cellular Therapeutics.
The American Association for Cancer Research delivered a letter to Rep. Kevin Brady (R-TX), conference chair of the House-Senate Conference Committee for the Tax Cuts and Jobs Act [HR 1], urging the committee to remove two provisions from the tax reform bill that, if enacted, would negatively impact cancer researchers and patients.
Bayer and the American Association for Cancer Research announced the 2017 AACR-Bayer Innovation and Discovery Grants.
The U.S. Preventive Services Task Force recommended against the use of hormone therapy to prevent chronic conditions in postmenopausal women, giving the modality D recommendations.
Jason Incorvati will join the department of hematology/oncology as an assistant professor, and will treat patients at the new Fox Chase Cancer Center East Norriton Hospital Outpatient Center.
Five health care systems have joined a precision oncology network that sequences patients' tumors at no cost and matches patients to clinical trials.
In his first talk to NCI staff, director Norman “Ned” Sharpless presented himself as an institute insider—highlighting his career-long relationships with NCI and its “legends,” demonstrating his grasp of the institute's agenda and research portfolio.
